ST GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News:
At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.
In view of the current situation and based on Art. 6a of Ordinance 2, issued by the Swiss Federal Council, regarding measures against containment of the coronavirus (COVID-19), shareholders were not permitted to attend the event in person. Shareholders exercised their rights exclusively through the independent proxy and 69% of the share capital was represented.
Shareholder approvals
Shareholders approved the 2019 Vifor Pharma Annual Report, the Vifor Pharma Ltd. 2019 Annual Financial Statements, and the Vifor Pharma Group 2019 Consolidated Financial Statements as well as an extension of the Authorized Capital until 14 May 2022 by approving the respective amendment to the Articles of Association. The maximum possible 2020 remuneration for the Board of Directors and Executive Committee was also approved, as well as the 2019 Remuneration Report in a consultative vote. Shareholders discharged the members of the Board of Directors and the Corporate Executive Committee for the financial year 2019. A dividend of CHF 2.00, as proposed by the Board of Directors, was approved and will be paid to shareholders on 20 May 2020.
Board of Directors re-elections
The Annual General Meeting re-elected all members proposed and elected Gilbert Achermann as new member of the Board of Directors. Shareholders also elected Jacques Theurillat as new Chairman of the Board of Directors, succeeding Etienne Jornod who decided not stand for re-election after 25 years. The Board of Directors sincerely thanks him for many years of distinguished service and recognized his long-standing and successful leadership by appointing him as Honorary Chairman.
The Board of Directors is now composed of the following members: Jacques Theurillat (Chairman), Gilbert Achermann, Prof. Dr. hon. Michel Burnier, Dr. Romeo Cerutti, Dr. Sue Mahony, Kim Stratton and Dr. Gianni Zampieri.
Remuneration Committee confirmed
The following members of the Board of Directors were re-elected to the Remuneration Committee for a term of one year: Prof. Dr. hon. Michel Burnier, Dr. Romeo Cerutti, and Dr. Sue Mahony.
Vifor Pharma Group is a global specialty pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
Carestream Health将其医疗保健IT业务
Vifor Pharma and Angion
Rimini Street荣获多项客户销售与服务世界奖
DCAS开始接受2024年非经销商委员会会员申请
Spesolimab meets primary
Aeternals:新型NFT和互动技术相结合
Boehringer Ingelheim Launches
聚豪情商务联盟携手天赐良田,玖夫牌富硒大米
Sabre选择DXC Technology来助力改变未
面对疫情和经济危机,亿康先达发布强劲的20
苏爱康医药宣布在日本推出Darvias®
Mythical Games完成3700万美元C1轮融资
IDEMIA和Resa Airport Data Syst
回顾激情燃烧的建设岁月 传承兰西拉艰苦奋斗
Kymeta 宣布其下一代天线、终端和全球移动连接
电池生产商Hithium将为储能系统开发商Perfect
Mavenir的虚拟无线接入网(vRAN)连续第二年在
村田首款面向Wi-Fi 6E/7的寄生元件耦合器实现商
在大地上书写责任与担当——渭南师范学院孙樵
全球投资者法律顾问ROSEN鼓励Athira Pharma
Intelsat向史密森国家航空航天博物馆捐赠
森永乳业的益生菌长双歧杆菌BB536在其50周年庆
深圳三匹马出行科技与江铃集团新能源战略合作
广成明股份参加番禺区先进制造业强区座谈会